ACADIA Pharmaceuticals Inc.
NASDAQACAD enters its August 6 earnings report with the Street raising targets on the same day the stock gained 6%, a rare confluence that sharpens the focus on what management says next. The analyst moves this week tell a consistent story: the direction is up. Three firms raised price targets on August 5 alone — RBC Capital moved to $37, Citizens to $36, and Oppenheimer to $25. The…
ACAD short interest plunges 25% in one week to 6.2% of float, lowest in months. Shares short fell to 10.5M from 14.1M as covering accelerates. Cost to borrow ticks up to 0.52%, while massive availability (1,819% of SI) suggests few constraints on new shorts entering. Near-term technicals softening despite analyst support at $32.65 target.
ACAD enters its August 6 earnings report with the Street raising targets on the same day the stock gained 6%, a rare confluence that sharpens the focus on what management says next. The analyst moves this week tell a…
ACAD heads into its August 6 earnings report with bears in full retreat and options traders positioned firmly on the bullish side. The most striking shift in the setup is the dramatic unwind of short positions. Short…
Snapshot as of 6 Aug 2026
ACADIA Pharmaceuticals enters the week of its earnings release with short interest at a four-month high — up 25% in just one month — yet the borrow market remains so loose it barely registers as friction. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACAD — free to start on ORTEX.
Sign up for free →Open ACAD on ORTEX